or Try an Advanced Search...

    Technical Analysis for BCAB - BioAtla, Inc.

    Grade Last Price % Change Price Change
    F 1.35 -1.46% -0.02
    BCAB closed down 1.46 percent on Monday, July 1, 2024, on 1.21 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BCAB trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    Doji - Bullish? Reversal 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Volume Surge Other -1.46%
    Bollinger Band Squeeze Range Contraction -1.46%
    Lower Bollinger Band Walk Weakness -1.46%
    Stochastic Reached Oversold Weakness -1.46%
    Older End-of-Day Signals for BCAB ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 5% about 9 hours ago
    Down 3% about 10 hours ago
    1.5x Volume Pace about 10 hours ago
    Rose Above Lower Bollinger Band about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BCAB Chart by TradingView
    Basic chart:

    Profile

    BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Bladder Cancer Hepatocellular Carcinoma NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer

    Is BCAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
    May 29 BioAtla to Participate in the Jefferies Global Healthcare Conference
    May 23 BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 23 Institutional owners may consider drastic measures as BioAtla, Inc.'s (NASDAQ:BCAB) recent US$35m drop adds to long-term losses
    May 15 BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
    May 15 BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
    May 14 BioAtla GAAP EPS of -$0.48 beats by $0.06
    May 14 BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
    May 8 BioAtla to Participate in the Citizens JMP Life Sciences Conference
    May 7 BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
    See more BCAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.02
    52 Week Low 1.24
    Average Volume 861,416
    200-Day Moving Average 2.17
    50-Day Moving Average 2.11
    20-Day Moving Average 1.54
    10-Day Moving Average 1.48
    Average True Range 0.20
    RSI (14) 35.06
    ADX 27.65
    +DI 12.03
    -DI 26.59
    Chandelier Exit (Long, 3 ATRs) 1.24
    Chandelier Exit (Short, 3 ATRs) 1.88
    Upper Bollinger Bands 1.73
    Lower Bollinger Band 1.35
    Percent B (%b) 0.01
    BandWidth 24.80
    MACD Line -0.20
    MACD Signal Line -0.22
    MACD Histogram 0.0226
    Fundamentals Value
    Market Cap 64.71 Million
    Num Shares 47.9 Million
    EPS -2.65
    Price-to-Earnings (P/E) Ratio -0.51
    Price-to-Sales 989.22
    Price-to-Book 1.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.52
    Resistance 3 (R3) 1.52 1.46 1.49
    Resistance 2 (R2) 1.46 1.42 1.46 1.48
    Resistance 1 (R1) 1.41 1.39 1.44 1.41 1.47
    Pivot Point 1.35 1.35 1.36 1.35 1.35
    Support 1 (S1) 1.29 1.30 1.32 1.29 1.23
    Support 2 (S2) 1.23 1.28 1.23 1.22
    Support 3 (S3) 1.18 1.23 1.21
    Support 4 (S4) 1.18